Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG

Bone Marrow Transplantation

Volumn 46, Issue 8, 2011, Pages 1077-1083

  El Kourashy, S ^a,d   Williamson, T ^b   Chaudhry, M A ^a   Savoie, M L ^a   Turner, A R ^c   Larratt, L ^c   Storek, J ^a   Bahlis, N J ^a   Brown, C B ^a   Yang, M ^a   Quinlan, D ^a   Geddes, M ^a   Zacarias, N ^a   Daly, A ^a   Duggan, P ^a   Stewart, D A ^a   Russell, J A ^a  

^a FOOTHILLS HOSPITAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

age; comorbidity; HCT CI; myeloablative

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; FOLINIC ACID; METHOTREXATE; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; CANCER RELAPSE; COMORBIDITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; ENGRAFTMENT; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; SCORING SYSTEM; THERAPY EFFECT; TREATMENT OUTCOME; WHOLE BODY RADIATION;

AGE FACTORS; AGED; ANTILYMPHOCYTE SERUM; BUSULFAN; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 80051674463     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.257     Document Type: Article

References (33)

1. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919. (Pubitemid 41510773)
2. Sorror ML, Giralt S, Sandmaier BM, Delima M, Shahjahan M, Maloney DG et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007; 110: 4606-4613. (Pubitemid 351377830)
3. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961-968. (Pubitemid 39038014)
4. Banna GL, Aversa S, Sileni VC, Favaretto A, Ghiotto C, Monfardini S. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. Crit Rev Oncol Hematol 2004; 51: 171-189. (Pubitemid 39158687)
5. Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. Leukemia 2006; 20: 1661-1672. (Pubitemid 44574980)
6. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the acute leukemia working party (ALWP) of the European group for blood and marrow transplantation (EBMT). Leukemia 2005; 19: 2304-2312. (Pubitemid 41748028)
7. de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, lppoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hema-topoietic stem cell transplantation. Blood 2004; 104: 865-872. (Pubitemid 38970586)
8. Shimoni A, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Benbassar I et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322-328. (Pubitemid 43148672)
9. Alyea EP, Kim HT, Ho V, Culter C, DeAngelo DJ, Stone R et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12: 1047-1055. (Pubitemid 44603937)
10. Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007; 25: 4246-4254. (Pubitemid 47554249)
11. Russell JA, Tran HT, Quinlan D, Chaudbry A, Duggan P, Stewart D et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468-476. (Pubitemid 35174820)
12. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857-864. (Pubitemid 38970585)
13. Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007; 13: 814-821. (Pubitemid 46902436)
14. Russell JA, Chaudhry A, Booth K, Brown C, Woodman RC, Valentine K et al. Early outcomes after allogeneic stem cell transplantation for leukemia and myelodysplasia without protective isolation: a 10-year experience. Biol Blood Marrow Transplant 2000; 6: 109-114.
15. Russell JA, Woodman RC, Poon MC, Jones AR, Ruether BA. Addition of low-dose folinic acid to a methotrexate/cyclospor-in A regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1994; 14: 397-401. (Pubitemid 24295232)
16. Barrett J. Graft-versus-host disease. In: Treleaven J BJ (ed). Bone Marrow Transplantation in Practice. Edinburgh: Churchill Livingstone, 1992: 257.
17. Chapiro E, Russell L, Lainey E, Kaltenbach S, Della-Valle V, Hanssens K et al. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia. Leukemia 2010; 24: 642-645.
18. Guilfoyle R, Demers A, Bredeson C, Richardson E, Szwajcer D, Sftel MD et al. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 2009; 43: 133-139.
19. Labonte L, Iqbal T, Zaidi MA, McDiarmid SA, Hubscb LB, Tay J et al. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hemato-poietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 1039-1044.
20. Majhail NS, Brunstein CG, McAvoy S, Defor TE, AL-Hazzouri A, Setubal D et al. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant 2008; 14: 985-992.
21. Pollack SM, Steinberg SM, Odom J, Dean RM, Fowler DH, Bishop MR. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15: 223-230.
22. Wildes TM, Augustin KM, Sempek D, Zbang QJ, Viji R, Dipersio JF et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 840-846. (Pubitemid 351773161)
23. Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myelo-ablative allogeneic stem cell transplantation. Leukemia 2009; 23: 1131-1138.
24. Sorror ML, Storer B, Storb RF. Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. Biol Blood Marrow Transplant 2009; 15: 757-758.
25. Mielcarek M, Storer BE, Sandmaier BM, Sorror ML, Maloney DG, Petersdorf E et al. Comparable outcomes after non-myeloablative hematopoietic cell transplantation with unrelated and related donors. Biol Blood Marrow Transplant 2007; 13: 1499-1507. (Pubitemid 350091388)
26. Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992-2001. (Pubitemid 351574075)
27. Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111: 446-452.
28. Diaconescu R, Flowers CR, Storer B, Sorror ML, Maris MB, Maloney DG et al. Morbidity and mortality with nonmyeloa-blative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550-1558. (Pubitemid 39166537)
29. Barba P, Pinana JL, Martino R, Valcarcel D, Amoros A, Sureda A et al. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of TRM and OS in a population of patients undergoing allo-RIC. Biol Blood Marrow Transplant 2010; 16: 413-420.
30. Ringden O, Labopin M, Ehninger G, Neiderwieser D, Olsson R, Basara N et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570-4577.
31. Russell JA, Irish W, Balogh A, Chaudry MA, Savoie ML, Turner AR et al. The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. Biol Blood Marrow Transplant 2010; 16: 509-514.
32. Kasbia G, Al-Gahtani F, Tay J, Labonate L, Tinmouth A, Gillingham A et al. Reduced hemoglobin on day of peripheral blood progenitor cell collection is associated with low graft content of vascular progenitors and increased toxicity after autologous hematopoietic stem cell transplantation. Transfusion 2008; 48: 2421-2428.
33. Alatrash G, Andersson B, Pelosini M, Rondon G, Qazilbash S, Giralt S et al. Allogeneic hematopoietic stem cell transplant (HSCT) for patients in the 6th and 7th decades of life with AML or MDS using myeloablative, reduced toxicity IV busulfan/fludarabine (BuFlu) conditioning regimen Abstract, American Society for Blood and Marrow Transplantation 2009 BMT Tandem Meeting, 11-15 February 2009, Tampa, FL.